Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 14, 2006

IntegraGen SA Establishes a U.S. Subsidiary

  • IntegraGen SA established IntegraGen, Inc., as a wholly owned U.S. subsidiary, based in New York. Robert Gottlieb was named CEO. “With the incorporation of IntegraGen Inc., the IntegraGen Group has made a significant step forward, which allows the Group to effectively market its genetic testing services into this important market,” remarks Jan Mous, Ph.D., president and CEO of IntegraGen SA.

    IntegraGen has two commercial operations. Diagnostic testing and counselling services are offered through a Diabetes Competence Center, based in Bonn, Germany. A Genetic Services business, operating out of the company’s headquarters in Evry, France, provides customized genotyping and BAC array services.

    The company is currently focused on type 2 diabetes, obesity, autism, and bipolar disorder. Clinical trials for the company’s first genetic test for autism, based on internally identified genes, are planned for the first quarter of 2007.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »